Viking Therapeutics is trading at $36.38, down 12.64%, as financing terms heightened dilution concerns.
- On September 24, 2026, it priced an upsized $500 million financing: 7.86 million shares at $35.00 and $225 million in convertible notes.
- Potential conversion and the below-market share price raised concerns following the prior session’s 35.67% advance.
- Settlement is scheduled for September 25, 2026; broader biotech weakness and rising yields also weighed, though financing remained the primary catalyst.